Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.
Foresee's product portfolio includes late and early-stage programs.
CAMCEVI 6-month formulation, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan and Israel and launched in the U.S.. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted. For the second indication of CAMCEVI 42 mg, central precocious puberty (CPP), the Casppian phase 3 clinical study, has been initiated.
FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 POC study in allergic asthmatic patients. The study has been completed with positive outcomes, with future development in rare immune-fibrotic diseases. FP-020, a follow-on oral MMP-12 inhibitor, for which a Phase 1 study has been completed, with development targeted in severe asthma, COPD and IBD.
FP-045 is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is currently being initiated, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the fourth quarter of 2024. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space.
Company Details
- Employees
- 47
- Founded
- -
- Address
- No.19-3, Sanchong Rd., Nangang Dist., Taipei City, Taiwan, 9f-2,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.foreseepharma.com/
- Keywords
- Pharmaceuticals, Rare Disease, Oncology, Neuroscience, Urology, Pulmonary/Respiratory Diseases, Cardiology/Vascular Diseases, Biotechnology.
- HQ
- Taipei
Foresee Pharmaceuticals Questions
Foresee Pharmaceuticals's website is http://www.foreseepharma.com/
Foresee Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/foreseepharma
Foresee Pharmaceuticals has
47 employees.
View email and phone details for 47
employees at Foresee Pharmaceuticals.
Foresee Pharmaceuticals's industry is
Biotechnology Research
Foresee Pharmaceuticals's top competitors are
Lumosa Therapeutics Co., Ltd.,
Eli Lilly And Company,
Amneal Pharmaceuticals,
Bioboston Consulting,
Obi Pharma,
Dialectic Therapeutics Inc,
Daiichi Sankyo Us,
Tlc Biosciences,
Qps Holdings, Llc,
Eilean Therapeutics.
Foresee Pharmaceuticals's categories are Biotechnology Research
Foresee Pharmaceuticals's founding year is 2013
